News & Events
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.
READ MOREFDA Grants Crinetics Pharmaceuticals (CRNX) Orphan Drug Designation - Paltusotine for the Treatment of Acromegaly
The orphan drug designation by the FDA for paltusotine to treat acromegaly validates the encouraging clinical data we have seen so far in the Phase 2 ACROBAT Edge clinical trial, and underscores the need for a once daily oral treatment option for patients suffering from this rare disease,” said Michael Monahan, Senior Director of Regulatory Affairs at Crinetics. "
READ MORECrinetics Confirms Completion - Half of Enrolled Patients in Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine
28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands (SRLs) Recruitment for the Edge and Evolve trials has been completed with 47 and 13 patients, respectively, and topline data is planned for the fourth quarter of 2020. Management expects to use the results for the two trials to support the initiation of Phase 3 clinical development for paltusotine in the first half of 2021
READ MORECrinetics (CRNX) appointments Adriana Cabré, MBA - VP of HR
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) appointments Adriana Cabré, MBA, as Vice President of Human Resources.
READ MORECrinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly Completed successful public offering raising net proceeds of $107. 9 million SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.
READ MORECrinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Crinetics Pharmaceuticals (CRNX) announced today that it has closed its previously announced underwritten public offering of 8,222,500 shares of its common stock, including 1,072,500 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $14. 00 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $115.
READ MORECrinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Crinetics has closed its previously announced underwritten public offering of 8,222,500 shares of its common stock, including 1,072,500 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $14. 00 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $115.
READ MOREGlobal Genes - Crinetics Raises $100 Million to Advance Rare Endocrine Disease Pipeline
April 15, 2020 — Crinetics has raised $100 million via public offering of 7. 2 million shares of its stock to fund research for the treatment of rare diseases such as acromegaly, Cushing's disease, congenital hyperinsulinism, and congenital adrenal hyperplasia. Read the full article on Global Genes - Allies in Rare Disease.
READ MORECrinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Crinetics intends to use the net proceeds from the proposed offering to fund the development of paltusotine - for the treatment of acromegaly and neuroendocrine tumors (NETs) - and its other research and development programs, and for working capital and general corporate purposes.
READ MORECrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
